Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #51 to #100.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. VT-122 (Propranolol and Etodolac combination)‏‎ (3 links)
  2. Valproic Acid/Sodium Valproate (Depakote)‏‎ (3 links)
  3. 13.5 months for general cases, 19.5 months for patients with MGMT methylated tumors.‏‎ (2 links)
  4. 14-16 months with standard treatment.‏‎ (2 links)
  5. 16 months (control group in EF-14 Trial)‏‎ (2 links)
  6. 17% in the study of patients with tumors recurring after radiation; 38% in a study using PCV for tumors recurrent after radiation (and for some after prior chemotherapy); 13% in a study with PCV after Temodar failure‏‎ (2 links)
  7. 17 months for general cases, 25.5 months for patients with MGMT methylated tumors when administered in the morning.‏‎ (2 links)
  8. 1 out of 16 patients was alive after one year.‏‎ (2 links)
  9. 20.9 months (Optune plus temozolomide, final EF-14 analysis)‏‎ (2 links)
  10. 23 months median survival, with 47% at 2 years‏‎ (2 links)
  11. 3 (awaiting research)‏‎ (2 links)
  12. 4.5‏‎ (2 links)
  13. 5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.‏‎ (2 links)
  14. 6 out of 14 patients were alive after one year‏‎ (2 links)
  15. 8.0 months mOS observed in phase 2 trial for patients receiving treatment dose of 30 mg/m2/day‏‎ (2 links)
  16. AVAglio trial: 16.8 months; RTOG trial: 15.7 months‏‎ (2 links)
  17. Based on available data, potentially highly useful in specific dosing schedules‏‎ (2 links)
  18. Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors.‏‎ (2 links)
  19. Comparable to standard treatment, specifics depend on individual patient factors.‏‎ (2 links)
  20. Data varies; traditional radiation therapies offer median OS of around 16-21 months for glioblastoma‏‎ (2 links)
  21. Early clinical evaluation in a small case series‏‎ (2 links)
  22. Early clinical trials show promising results in improving overall survival and progression-free survival in various cancers, including potential benefits for GBM. Ongoing trials will provide more definitive data.‏‎ (2 links)
  23. Early studies indicate variable results; ongoing trials, including combinations with PARP inhibitors, aim to determine efficacy‏‎ (2 links)
  24. Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts‏‎ (2 links)
  25. Enhancements in progression-free survival noted in combination therapies, ranging from improvement in median progression-free survival times to higher 6-month survival rates‏‎ (2 links)
  26. Fatigue, dizziness, nausea, mouth irritation‏‎ (2 links)
  27. Gamma-Linolenic Acid (GLA)‏‎ (2 links)
  28. Gamma Knife Radiosurgery (GKRS) for GBM‏‎ (2 links)
  29. Hematological toxicity, nausea, and neurological effects‏‎ (2 links)
  30. High-dose PBT showed a median OS of 65.6 months for patients with radiation necrosis, and 26.9 months for patients without radiation necrosis in specific studies‏‎ (2 links)
  31. Historical mOS for similar patient population using lomustine is 7.2 months‏‎ (2 links)
  32. Hyperthermia has shown potential in enhancing the effectiveness of radiation and chemotherapy, improving overall survival and progression-free survival rates in glioblastoma patients.‏‎ (2 links)
  33. ICT-107 (Tumor-associated Antigen Vaccine)‏‎ (2 links)
  34. Improved PFS observed with PBT, specific rates vary by study‏‎ (2 links)
  35. Improved in morning dosing, exact data still under investigation.‏‎ (2 links)
  36. Increases observed in specific combination trials, such as Irinotecan with Bevacizumab‏‎ (2 links)
  37. Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies.‏‎ (2 links)
  38. Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months‏‎ (2 links)
  39. Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence‏‎ (2 links)
  40. Median overall survival for GBM typically ranges around 16 months with standard treatment.‏‎ (2 links)
  41. Median progression-free survival with standard treatments is about 6-9 months for GBM‏‎ (2 links)
  42. Median survival with standard treatment: 17.4 months‏‎ (2 links)
  43. Metronomic Low-Dose Temozolomide (TMZ)‏‎ (2 links)
  44. Metronomic low-dose TMZ may offer a viable option for patients with recurrent GBM, providing a balance between efficacy and reduced toxicity compared to standard dosing. Further research is ongoing to confirm these benefits.‏‎ (2 links)
  45. Not applicable; research has not extensively measured progression-free survival in cancer patients‏‎ (2 links)
  46. Not directly specified; historical control data needed for comprehensive comparison‏‎ (2 links)
  47. Not directly specified; improvements noted in selected patient analyses‏‎ (2 links)
  48. Not directly specified; ongoing studies aim to clarify Carboplatin's impact on survival in recurrent glioma‏‎ (2 links)
  49. Not explicitly detailed in recent reviews‏‎ (2 links)
  50. Not fully established from available data‏‎ (2 links)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"